NVision raises $55 million to scale quantum platform for drug discovery
NVision raises $55 million to expand its quantum platform from sensing to computing, accelerating MRI-based diagnostics and drug discovery for cancer care.
NVision, the Ulm-based quantum technology company, said it has closed a $55 million Series B financing round to accelerate development of its technical platform and move from sensor applications toward quantum computing capabilities. The funding will support work to adapt the company’s sensor-first systems into a computing architecture intended to speed discovery of new drugs and therapies. NVision, which has focused on biomedical uses since its founding a decade ago, said the investment will underpin expansions in both hardware and applied life-science programs.
Series B financing led by Abbott
The new round was led by medical diagnostics and devices firm Abbott and includes a venture loan from the European Investment Bank, NVision reported. Additional investors cited by the company include Playground Global, Matterwave/b2venture and Entrée Capital. With this injection, NVision’s total capital raised to date rises to approximately $120 million, positioning the firm to scale development and commercialization efforts.
Platform shift from sensor to computing
Company executives have described the financing as a bridge from sensor innovation to a broader computing platform. Engineers will use the proceeds to extend the Polaris sensor platform’s capabilities and to develop PIQC, NVision’s nascent quantum computing architecture built on organic photonic components. Management said the roadmap prioritizes integration with existing clinical and research equipment to accelerate adoption.
Polaris MRI enhancement and clinical impact
NVision’s Polaris system amplifies MRI signals from sugar-based contrast agents, enabling clinicians to observe complex metabolic processes with greater sensitivity and speed. The company says Polaris can compress diagnostic timelines for therapy assessment from weeks or months to a matter of hours by delivering near-immediate metabolic readouts. Polaris is designed to interface with standard MRI hardware, allowing research centers and hospitals to adopt the technology without replacing existing scanners.
Discovery of organic qubits and PIQC development
While developing MRI signal amplification, NVision researchers identified photon-emitting organic molecules with properties suitable for qubit formation. The firm says these organic qubits can be manufactured in thin layers on photonic chips and may offer a pathway to a scalable quantum computing platform. NVision’s PIQC concept aims to combine those organic qubits with photonic integration, creating an architecture intended to address computational challenges in molecular modeling and drug discovery.
The company argues that organic qubits offer practical advantages for integration with photonic systems and for hybrid approaches that combine classical and quantum processing. NVision plans to use the new funding to advance materials science, chip integration and the software stack required to run biomedical workloads on PIQC.
Collaborations and planned deployments
NVision reported that several research hospitals and university centers are already testing Polaris and that the company expects deployment at roughly 20 sites across the United States, Asia and Europe by the end of the year. Named collaborators include institutions in Cambridge, the Memorial Sloan Kettering Cancer Center in New York and the Technical University of Munich. These partnerships are intended to validate clinical workflows, gather translational data and demonstrate the system’s utility for therapy evaluation and biomarker-driven studies.
Strategic position in a growing quantum-biomed sector
NVision is one of some fifty startups in Germany focused on quantum technologies and operates amid a broader ecosystem of about a hundred public research institutions working on quantum science. By concentrating on biomedical applications, NVision is positioning itself at the intersection of quantum sensing, imaging and computational drug discovery. Investors backing the round emphasized the potential for quantum-enabled tools to generate novel drug hypotheses and to accelerate development timelines for conditions that remain difficult to treat.
The company says its existing products and services are already on the market and that the Series B proceeds will both expand commercial deployments and fund the R&D needed to bring PIQC from prototype toward a production-capable platform.
NVision’s leadership frames the effort as a long-term push to make quantum-derived insights routine in biomedical research, with short-term targets focused on clinical validation and integration with standard imaging infrastructure.
The funding round and immediate deployment plans mark a significant step for NVision as it seeks to translate quantum-enabled sensing into computational tools for drug discovery and clinical decision support.
